I was wondering if forum members know of any promising intervention/therapy that has been shown to induce partial regression of established fibrosis. Interested in both mechanistic evidence and personal N=1 experiences: have stem cells or exosomes produced noticeable fibrosis regression for anyone?
Personally I thought the Endostatin 4 peptide looked interesting, but with many caveats. The summary below is an AI-draft - admittedly I haven’t fact-checked every detail.
Here you can find more info about this Endostatin-derived peptide E4: News & Updates - Thendor Therapeutics
E4 / Endostatin-derived antifibrotic peptides / END55)**
Endostatin-derived peptides and antifibrotic discovery
Endostatin is a naturally occurring fragment of collagen XVIII originally studied for its anti-angiogenic properties in cancer biology. Subsequent research revealed that smaller peptide regions derived from endostatin can also influence extracellular matrix (ECM) remodeling and fibrosis.
From this work, researchers identified a short peptide region called E4, derived from endostatin, which showed unexpected and strong antifibrotic activity.
The key early study demonstrated that E4:
- reduced TGF-β–induced fibrotic activation,
- decreased collagen deposition,
- and could attenuate both preventive and established fibrosis in experimental systems.
It was effective in:
- mouse models of dermal and pulmonary fibrosis,
- human fibroblast systems,
- and ex vivo human fibrotic tissue explants.
Key advancement: E4 can reverse established fibrosis
A major and unusual feature of E4 (compared with many antifibrotic candidates) is that it was reported to not only prevent fibrosis, but also partially reverse pre-existing fibrotic tissue changes in preclinical models.
This is important because established fibrosis is typically stabilized by:
- dense collagen crosslinking,
- activated myofibroblasts,
- ECM stiffening,
- and self-sustaining signaling loops.
Refined mechanism (updated with 2021–2022 findings)
Earlier interpretations emphasized general suppression of:
- TGF-β signaling,
- collagen production,
- LOX-mediated crosslinking,
- and fibroblast activation.
However, later mechanistic work significantly clarified the primary pathway.
Primary mechanism: urokinase pathway activation
The 2021–2022 MUSC/JCI Insight work showed that E4 acts by:
- binding to uPAR (urokinase plasminogen activator receptor) and enolase-1
- activating the urokinase plasminogen activation system (uPA/uPAR axis)
This leads to:
- increased activation of proteolytic cascades that degrade excess ECM,
- suppression of further collagen accumulation,
- reversal of fibrotic remodeling programs.
In simpler terms:
E4 appears to shift tissue balance toward matrix breakdown and remodeling, rather than just suppressing fibrotic signaling.
This is a major refinement because it identifies a specific receptor-mediated pathway, rather than a broad indirect effect.
Secondary or downstream effects (reinterpreted)
Effects previously attributed as “direct actions” may now be better understood as downstream consequences of urokinase activation:
- reduced collagen accumulation → likely secondary to increased ECM degradation
- changes in LOX expression → downstream of altered ECM turnover
- reduced fibroblast activation → indirect consequence of altered matrix signaling environment
- modulation of TGF-β signaling → potentially downstream or parallel, not primary driver
Human relevance and translational strength
A key strength of the research program is the consistent use of:
- human fibroblasts,
- human lung and skin tissue explants,
- and mouse models of induced fibrosis.
Importantly, E4 showed activity in human fibrotic lung tissue ex vivo, including tissue resembling advanced-stage disease, supporting translational relevance.
However, these systems still do not replicate:
- full pharmacokinetics,
- immune interactions,
- long-term tissue remodeling dynamics,
- or whole-organ physiology.
Endostatin-derived biology and therapeutic development (END55)
Because E4 is a small peptide, it likely has limitations typical of peptide therapeutics:
- rapid degradation,
- short half-life,
- and rapid renal clearance.
To address this, researchers developed END55, an engineered Fc-fusion protein based on the E4 region.
END55 was designed to:
- extend circulation time via Fc recycling,
- improve stability,
- enhance systemic exposure,
- and improve drug-like behavior.
This represents a classic biologic optimization strategy: converting a short-lived active peptide into a long-acting therapeutic protein.
Important tradeoff: potency vs delivery
| Feature | E4 peptide | END55 Fc-fusion |
|---|---|---|
| Biological specificity | High | High |
| Half-life | Short | Long |
| Tissue penetration | Likely better | Possibly reduced |
| Systemic exposure | Low | High |
| Drug development suitability | Limited | Improved |
A key unresolved question is whether increased size (END55) improves overall efficacy in dense fibrotic tissue, which is often poorly vascularized.
Disease context and limitations
Fibrosis (e.g., idiopathic pulmonary fibrosis, systemic sclerosis, liver cirrhosis) is characterized by:
- self-sustaining ECM accumulation,
- mechanical tissue stiffening,
- and persistent fibroblast activation loops.
Many compounds that reverse fibrosis in bleomycin mouse models fail in humans because:
- mouse fibrosis is more reversible,
- disease duration is short,
- and structural ECM remodeling is less entrenched.
Thus, while E4/END55 biology is compelling, the central clinical question remains:
Can this pathway produce meaningful reversal of established human organ fibrosis in vivo?
Overall updated interpretation
The current best-supported interpretation is:
- E4 is a biologically active endostatin-derived peptide with reproducible antifibrotic effects in experimental systems.
- Its most important validated mechanism is activation of the urokinase (uPA/uPAR) system via enolase-1 binding, leading to enhanced ECM remodeling.
- Earlier proposed mechanisms (TGF-β suppression, LOX reduction, VEGF-related effects) are likely secondary or context-dependent rather than primary drivers.
- END55 is a pharmacokinetic optimization designed to improve clinical viability rather than change mechanism.
- The key uncertainty is not whether the pathway exists, but whether it can be safely and effectively translated into meaningful reversal of advanced human fibrosis.
"